This is the case of the CCL2/CCR2 axis, which plays a role in the recruitment of monocytes in tumors: the CCR2 antagonist (PF-04136309) enhanced anti-tumor immunity, decreased tumor growth, and reduced metastasis in an orthotropic model of pancreatic cancer [59]. Here, CCL2 is linked to pancreatic neoplasm.